0% found this document useful (0 votes)

191 views3 pages

CV Kalev Kask - 2019

Kalev Kask has over 30 years of experience in neuroscience research and biotechnology. He received his PhD in neurochemistry from Stockholm University and conducted postdoctoral research at the Max Planck Institute. Kask has held leadership roles at several biotech startups, including founding EGeen International Corporation and Mango Biotechnology. He currently serves as the Director of the Board at Saturn Biosciences, where he is spearheading the development of an immuno-oncology therapy. Kask has authored multiple peer-reviewed publications and holds two patents.

Uploaded by

Anonymous KTkNT1b18

We take content rights seriously. If you suspect this is your content, claim it here.

Available Formats

Download as PDF, TXT or read online on Scribd

0% found this document useful (0 votes)

191 views3 pages

CV Kalev Kask - 2019

Uploaded by

Anonymous KTkNT1b18

We take content rights seriously. If you suspect this is your content, claim it here.

Available Formats

Download as PDF, TXT or read online on Scribd

You are on page 1/ 3

Kalev Kask

Mountain View, CA

1. University/undergraduate studies 1989

Bachelor/Master of Sciences cum laude, Tartu University, Estonia

2. Graduate studies 1990-1996

Ph.D. in neurochemistry, Stockholm University, Sweden.

3. Postgraduate education 1996-1998

An EMBO post-doctoral fellow in the laboratory of professor P. H. Seeburg, Max-

Planck-Institute for Medical Research, Heidelberg, Germany

4. Fellowships and awards

1991 - 1993 - the Swedish Institute scholarship

1995 - the EMBO long term fellowship for post-doctoral studies for 1996-1998
1995 - the Young Scientist Award of the International Society for Neurochemistry at the
Summer Neuropeptide Meeting, Martha’s Vineyard, June 1995

5. Professional experience

Solis Biodyne, Tartu, Estonia 1998

Marketing advisor

Introduced Solis's unique, room temperature stable PCR reagents to clients in the
US which enabled to get the company off the ground to become a significant
European player in the PCR and related technologies market.

AGY Therapeutics, South San Francisco, CA 1998-2000

Senior scientist, Head of Protein Interaction Group

Joined at early stages of this neurogenomics start-up. Participated in formulating

the research strategy, built and a led a group of scientists to analyze function of
disease relevant drug targets.

Ingenuity Systems, Alviso, CA 2000-2000

Knowledge base scientist, Pathways Group

Built with a group of scientists a knowledge base of cellular signaling pathways.

Stanford University, Palo Alto, CA 2000-2001

Research Associate, Department of Neurobiology

Supervised PhD students in new drug target discovery

Toshiba, Japan 2000-2001

Advisor, Biochip strategy

Asper Biotech, Mountain View, CA 2000-2001

Advisor, US Marketing and Intellectual Property

Successfully negotiated a necessary license from Orchid Biosciences granting

Asper freedom to operate using primer-extension technology.

EGeen International Corporation, Mountain View, CA 2001- to date

Founder and Chief Executive Officer

A hands-on leader with an excellent command of marketing clinical research and

all the operational details, focused mindset and ability to see company through
various stages of developemnt.
Raised successful rounds of financing from venture capital and private equity
investors, worked closely with them providing strategic leadership at various
stages of the company growing it from a pharmacogenomics focused start-up to a
high-performance, creative and profitable transatlantic clinical research
organization. Demonstrated superb marketing and financial management skills
with a focus on top- and bottomline. Creative and skilled deal negotiator with a
proven ability to close. Instilled the emphasis on customer service,
responsiveness, and data quality in the entire company while adhering to cost-
effectiveness of services. Entrepreneurial and driven, constantly pursued various
growth initiatives to maximize the overall value of the business.
Consummate networker with a large personal network of business development
and executive level contacts in the US, Europe and Asia. Well connected to the
top people in health care investment banking in Europe, New York and in the San
Francisco Bay Area. Great communicator both in- and outside of the company,
highly experienced in multicultural settings and diverse environments.

Mango Biotechnology (fka OAK Biotechnologies), Mountain View, CA 2007-to date

Founder and Managing Partner

Introduced Solis Biodyne's (SBD's) unique protein manufacturing technology to
Wilson Sonsini Goodrich Rosati, a leading US intellectual property (IP) law form,
to ensure that this technology has a proper IP protection to strengthen Solis's
market position. Became a sole representative of SBD in the US market.

Saturn Biosciences, Cambridge, UK/Mountain View, CA 2015-to date

Director of the Board

Spearheaded outlicensing of intratumorally targeted interleukin 12, a clinical stage

immuno-oncology asset, from a EU/US-based multinational pharmaceutical company
and devised and executed selective outlicensing of limited (either geographic, indication
or therapy-oriented) rights strategy to fund the clinical and corporate development of this
asset to improve the response of cancer patients to checkpoint inhibitors and other cancer
immunotherapeutics.